Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant

Zafer Cebeci, Nur KirDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, TurkeyAbstract: Diabetic macular edema (DME) is the leading cause of sight-threatening complication in diabetic patients, and several treatment modalities have been developed and eval...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cebeci Z, Kir N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/3d910ec09e4f4d8582c922d93f2ae167
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d910ec09e4f4d8582c922d93f2ae167
record_format	dspace
spelling	oai:doaj.org-article:3d910ec09e4f4d8582c922d93f2ae1672021-12-02T03:00:25ZRole of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant1178-7007https://doaj.org/article/3d910ec09e4f4d8582c922d93f2ae1672015-11-01T00:00:00Zhttps://www.dovepress.com/role-of-implants-in-the-treatment-of-diabetic-macular-edema-focus-on-t-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Zafer Cebeci, Nur KirDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, TurkeyAbstract: Diabetic macular edema (DME) is the leading cause of sight-threatening complication in diabetic patients, and several treatment modalities have been developed and evaluated to treat this pathology. Intravitreal agents, such as anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids, have become more popular in recent years and are widely used for treating DME. Sustained release drugs appear to be mentioned more often nowadays for extending the period of intravitreal activity, and corticosteroids play a key role in inhibiting the inflammatory process in DME. A potent corticosteroid, dexamethasone (Ozurdex®), in the form of an intravitreal implant, has been approved for various ocular etiologies among which DME is also one. This review evaluates the role of implants in the treatment of DME, mainly focusing on the dexamethasone intravitreal implant.Keywords: diabetes mellitus, diabetic macular edema, vascular endothelial growth factor, dexamethasone, Iluvien, corticosteroidCebeci ZKir NDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 555-566 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Cebeci Z Kir N Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
description	Zafer Cebeci, Nur KirDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, TurkeyAbstract: Diabetic macular edema (DME) is the leading cause of sight-threatening complication in diabetic patients, and several treatment modalities have been developed and evaluated to treat this pathology. Intravitreal agents, such as anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids, have become more popular in recent years and are widely used for treating DME. Sustained release drugs appear to be mentioned more often nowadays for extending the period of intravitreal activity, and corticosteroids play a key role in inhibiting the inflammatory process in DME. A potent corticosteroid, dexamethasone (Ozurdex®), in the form of an intravitreal implant, has been approved for various ocular etiologies among which DME is also one. This review evaluates the role of implants in the treatment of DME, mainly focusing on the dexamethasone intravitreal implant.Keywords: diabetes mellitus, diabetic macular edema, vascular endothelial growth factor, dexamethasone, Iluvien, corticosteroid
format	article
author	Cebeci Z Kir N
author_facet	Cebeci Z Kir N
author_sort	Cebeci Z
title	Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
title_short	Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
title_full	Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
title_fullStr	Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
title_full_unstemmed	Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
title_sort	role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/3d910ec09e4f4d8582c922d93f2ae167
work_keys_str_mv	AT cebeciz roleofimplantsinthetreatmentofdiabeticmacularedemafocusonthedexamethasoneintravitrealimplant AT kirn roleofimplantsinthetreatmentofdiabeticmacularedemafocusonthedexamethasoneintravitrealimplant
_version_	1718401978499858432

Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant

Ejemplares similares